MorphoSys: A European Champion Crossing The Biopharma Rubicon
MorphoSys: A European Champion Crossing The Biopharma Rubicon
$200.00
MorphoSys, out of Munich, is one of a handful of mature European biotech companies appearing ready for greatness. In Vivo spoke with the CEO about the firm’s next generation antibody platform and why US expansion is crucial to its future.
Author: Informa Pharma Intelligence
Publisher: InVivo
- Description
Unlike the many US success stories, there are virtually no European biotech companies breaking into the “Big League” of fully-fledged biopharma companies. In Vivo spoke with the CEO of one exception, Munich-based MorphoSys to provide more insight into Europe’s maturing biopharma marketing. MorphoSys now possesses an impressive pipeline of partnered and in-house molecules. Talking with In Vivo just weeks after taking the helm of the company, Jean-Paul Kress said he is focusing on flawless FDA filing of tafasitamab, establishing a strong commercial base in the US, and sealing a partnership to maximize the drug’s revenues.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Roche: We’ve Abandoned Budgets And It’s Liberated Employees 
Sign up to the